Fig. 2

Clinical responses mediated of BM38 CAR-Ts. a Swimmer plot for the 23 patients treated in the study. Two patients were enrolled in the two low-dose groups for the consideration of risk–benefit trade-off. b Immunohistochemical staining of patient 13’s right parailiac mass before treatment, showing involvement of MM cells and positive expression of BCMA and CD38. c Computed tomography scans of patient 13 showing a large right parailiac plasmacytoma at enrollment that was partially eliminated in month 3 and completely disappeared in month 5. d Changes of serum M protein in patient 13 during BM38 CAR-T treatment. e BCMA and CD38 expression on MM cells in patient 15 and 20 at baseline. Representative staining and gating of MM cells are shown in Additional file 1: Fig. S6